Coxibs: Evolution of prescription's behaviour in France

Fundamental and Clinical Pharmacology

Volumn 21, Issue 3, 2007, Pages 317-325

  Biga, Julie ^a,b   Gony, Mireille ^a   Bourrel, Robert ^c   Souche, Arnaud ^c   Sommet, Agnès ^a,b   Pathak, Atul ^a,b   Sciortino, Vincent ^c   Taboulet, Florence ^a   Grand, Alain ^a   Lapeyre Mestre, Maryse ^a,b   Montastruc, Jean Louis ^a,b  

^a UNIVERSITÉ PAUL SABATIER   (France)

^b TOULOUSE UNIVERSITY HOSPITAL   (France)

^c Caisse Nationale d'Assurance Maladie des Travailleurs Salaries   (France)

Author keywords

Coxibs; Health fund database; Non steroidal anti inflammatory drugs; Prescription's behaviours; Social pharmacology

Indexed keywords

CYCLOOXYGENASE 2 INHIBITOR; GASTROINTESTINAL AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN DERIVATIVE; PROTECTIVE AGENT; PROTON PUMP INHIBITOR; SUCRALFATE;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CHRONIC DISEASE; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CONSULTATION; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; FRANCE; GENERAL PRACTITIONER; HEALTH CARE COST; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL PRACTICE; PHARMACOEPIDEMIOLOGY; PRESCRIPTION; PRIORITY JOURNAL; REIMBURSEMENT; RHEUMATOLOGY; SEX RATIO;

ADOLESCENT; ADULT; AGED; CYCLOOXYGENASE 2 INHIBITORS; DRUG UTILIZATION; FEMALE; FRANCE; HUMANS; MALE; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; PHYSICIANS, FAMILY; RHEUMATOLOGY; SPECIALTIES, MEDICAL;

EID: 34249311934     PISSN: 07673981     EISSN: 14728206     Source Type: Journal    
DOI: 10.1111/j.1472-8206.2007.00489.x     Document Type: Article

References (30)

1. Ngoundo Mbongue T.B., Sommet A., Pathak A., Montastruc J.L. «Medicamentation» of the society, non-diseases and non-medications: a point of view from social pharmacology. Eur. J. Clin. Pharmacol. (2005) 61 309 313.
2. Montastruc J.L. La Pharmacologie Sociale: une nouvelle branche de la Pharmacologie Clinique. Therapie (2002) 57 420 426.
3. Wun Y.T., Chan C.S., Dickinson J.A. Determinants of physicians' attitude towards prescribing. J. Clin. Pharm. Ther. (2002) 27 57 65.
4. Anon. Rofecoxib in rheumatoid arthritis: new indication. No better that other NSAIDS. Prescrire Int. (2003) 12 89 90.
5. Anon. Review of coxib adverse effects notified in France. Prescrire Int. (2003) 12 21.
6. Montastruc J.L., Lapeyre-Mestre M., Gony M., Lugardon S., Bagheri H. Coxibs, which real therapeutic advance? Recent pharmacoepidemiological data. Therapie (2004) 59 201 205.
7. Laporte J.R., Ibanez L., Vidal X., Vendrell L., Leone R. Upper gastrointestinal bleeding associated with the use of NSAIDs: newer versus older agents. Drug Saf. (2004) 27 411 420.
8. Lugardon S., Lapeyre-Mestre M., Montastruc J.L. and the French Network of Pharmacovigilance Centres. Upper gastrointestinal adverse drug reactions and cyclo-oxygenase-2 inhibitors (celecoxib and rofecoxib): a case/non-case study from the French Pharmacovigilance database. Eur. J. Clin. Pharmacol. (2005) 60 673 677.
9. Jüni P., Nartey L., Reichenbach S., Sterchi R., Dieppe P.A., Egger M. Risk of cardiovascular events and rofecoxib: cumulative meta-analysis. Lancet (2004) 364 2021 2029.
10. Graham D.J., Campen D., Hui R. et al. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study. Lancet (2005) 365 475 481.
11. Aw T.J., Haas S.J., Liew D., Krum H. Meta-analysis of cyclooxygenase-2 inhibitors and their effects on blood pressure. Arch. Int. Med. (2005) 165 1 7.
12. Durrieu G., Olivier P., Montastruc J.L. and the French Network of Pharmacovigilance Centres. COX-2 inhibitors and arterial hypertension: an analysis of spontaneous case reports in the French Pharmacovigilance database. Eur. J. Clin. Pharmacol. (2005) 61 611 614.
13. Bresalier R.S., Sandler R.S., Quan H. et al. Adenomatous Polyp Prevention on Vioxx (APPROve) Trial Investigators. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N. Engl. J. Med. (2005) 352 1092 1102.
14. Florentinus S., Heerdink E., de Boer A., van Dijk L., Leufkens H. The trade-off between cardiovascular and gastrointestinal effects of rofecoxib. Pharmacoepidemiol. Drug Saf. (2005) 14 669.
15. Montastruc J.L., Bongard V., Lapeyre-Mestre M. Perception of the risk of gastrointestinal adverse drug reactions with non-steroidal anti-inflammatory drugs (including coxibs): differences among general practitioners, gastroenterologists and rheumatologists. Eur. J. Clin. Pharmacol. (2003) 59 685 688.
16. Bouee S., Charlemagne A., Fagnani F. et al. Changes in osteoarthritis management by general practitioners in the COX-2-inhibitors era-concomitant gastroprotective therapy. Joint Bone Spine (2004) 71 214 220.
17. Patino F.G., Allison J., Mudiano A. et al. The effects of Physician Specialty and patient comorbidities on the use and discontinuation of coxibs. Arthritis Rheum. (2003) 49 293 299.
18. Glaesmer H., Deter H.C. Gender-specific aspects of physicians work. Psychother. Psychosom. Med. Psychol. (2002) 52 386 391.
19. Sequeira R.P., Al Khaja K.A., Damanhori A.H., Mathur V.S. Physician gender and antihypertensive prescription pattern in primary care. J. Eval. Clin. Pract. (2003) 9 409 415.
20. Dybdahl T., Andersen M., Sondergaard J., Krasgstrup J., Kristiansen I.S. Does the early adopter of drugs exist? A population-based study of general practitioners' prescribing of new drugs. Eur. J. Clin. Pharmacol. (2004) 60 667 672.
21. Balsan D., Chambaretaud S. Les dépenses de médicaments remboursables entre 1998 et 2001. Etudes et résultats, Drees (2002) 166 1 8.
22. CNAMTS. Le secteur libéral des professionnels de santé en 2002. STAT (2003) 38 1 4.
23. CREDES. Questions d'économie de la santé. La diffusion de l'innovation pharmaceutique: revue de la littérature et premiers résultats français (2003) 73 1 4.
24. Delga C., Megnin Y., Oustric S. et al. A pilot study in general practice: pressure to prescribe. Therapie (2003) 58 513 517.
25. Teeling M., Bennett K., Feely J. Have COX-2 inhibitors influenced the co-prescription of anti-ulcer drugs with NSAIDs Br. J. Clin. Pharmacol. (2003) 57 337 343.
26. Bennett K., Teeling M., Feely J. ''Selective'' switching from non-selective to selective non-steroidal anti-inflammatory drugs. Eur. J. Clin. Pharmacol. (2003) 59 645 649.
27. Moride Y., Ducruet T., Boivin J.F., Moore N., Perreault S., Zhao S. Prescription channelling of COX-2 inhibitors and traditional nonselective nonsteroidal anti-inflammatory drugs: a population-based case-control study. Arthritis Res. Ther. (2005) 7 R333 R342.
28. Rawson N.S., Nourjah P., Grosser S.C., Graham D.J. Factors associated with celecoxib and rofecoxib utilization. Ann. Pharmacother. (2005) 39 597 602.
29. Cutts C., LaCaze A., Tett S. A clinical audit of the prescribing of ceclecoxib and rofecoxib in Australian rural general practice. Br. J. Clin. Pharmacol. (2002) 54 522 527.
30. Florentinus S.R., Nielsen M.W., Van Dijk L., Leufkens H.G.M., Holme Hansen E., Heerdink E.R. Patient characteristics associated with prescribing of a newly introduced drug: the case of rofecoxib. Eur. J. Clin. Pharmacol. (2005) 61 157 159.